NorthWest Biotherapeutics Inc (NWBO)

[Jesse James III]

Of course, I could be dead wrong Dok. Consider the following timeline (and other stuff):

1. On Feb 10th, Linda said DMC recommendation should come In a couple more weeks. This puts it at or around Feb. 24th.;

2. On Feb. 14th, Germany approves and publishes on Feb. 21st;

3. On March 7th, NWBO releases a statement: "Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today, in response to shareholder inquiries, that the Data Safety Monitoring Board (DSMB) has made an unblinded review of the safety data for the Company's ongoing international Phase III GBM Trial, and has recommended that the trial continue as planned."

The phrase "in response to shareholder inquiries" implies they had this info or requested it to quell shareholders - otherwise, why include that phrase?

I doubt Germany would roll the dice on minimal data, especially on a first immunotherapy, first non-German company, first cell therapy product, and only the 3rd approval in 2.5 years under section 4b.
No way.